Unaudited Results to 30 June 2023
Change of registered office
19 April 2022
ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces that it has changed its registered address to: First Floor, Zucchi Suite, Nostell Business Estate, Wakefield, WF4 1AB with immediate effect.
All formal notices and general correspondence should be sent to the new address.
For further information, please contact:
|Probiotix Health plc||Contact via Walbrook below|
|Stephen O’Hara, Chief Executive|
|Peterhouse Capital Limited||Tel: 020 7469 0930|
|Mark Anwyl (AQSE Corporate Adviser)|
|Duncan Vasey (Broker)|
|Walbrook PR Ltd||Mob: 07876 741 001 or [email protected]|
About ProBiotix Health plc
ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world.
ProBiotix Health’s cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (“LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.
Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube